2022 Revenues ($USD) : $19,487,900,000.00
2022 Revenues (foreign currencies) : €18,500,000,000
2022 R&D spend : $5,267,000,000.00
2022 Number of Employees : 53,155
Fiscal Year End : 12/31/22
Leader : Chair Hubertus von Baumbach

Boehringer Ingelheim, based in Ingelheim am Rhein, Germany, is the world's largest privately-owned pharmaceutical company, established in 1885. It has human health, animal health, and contract manufacturing divisions. The company has around a hundred drug candidates in pre-clinical and clinical development and anticipates numerous potential new medicine approvals within its pipeline over the next several years. In 2022, Boehringer Ingelheim reached more patients than ever, driven by innovative medicines. In June of the same year, the company signed an option to acquire Trutino Biosciences, a San Diego–based biotech company focused on next-generation cytokine therapies for immuno-oncology and autoimmune diseases. Boehringer Ingelheim also entered a global licensing agreement with Singapore's A*STAR to develop and commercialize innovative antibodies for targeted cancer therapies. —BB